Health Ministry Tightens Stem Cell Therapy Rules: Autism Treatment Only in Approved Clinical Trials

On 16 September 2026, the Union Ministry of Health and Family Welfare issued an advisory to States and Union Territories on stem cell therapy. It allows stem cell therapy as routine clinical care only for approved indications. For Autism Spectrum Disorder, any stem cell use is restricted to duly approved clinical trials. The advisory follows the Supreme Court's 30 January 2026 judgment in Yash Charitable Trust v. Union of India and a National Medical Commission advisory of 5 September 2026. It matters for exams because it links health regulation, medical ethics, patient rights and the federal structure.

What Happened

On 16 September 2026, the Union Ministry of Health and Family Welfare sent an advisory to States and UTs on regulating stem cell therapy. It permits stem cell therapy as routine care only for approved indications. Autism treatment with stem cells is allowed only inside approved clinical trials. The trigger was the Supreme Court's January 2026 ruling and a follow-up NMC advisory.

When & Where

Advisory: 16 September 2026, New Delhi; addressed to States and UTs that adopted the Clinical Establishments Act, 2010.
NMC advisory: 5 September 2026.
Supreme Court judgment: 30 January 2026.

Who Is Involved

Ministry of Health and Family Welfare — issued the advisory.
National Medical Commission (NMC) — regulates medical professionals; issued its own advisory.
ICMR and Department of Biotechnology (DBT) — jointly issued the National Guidelines for Stem Cell Research, 2017.
Supreme Court of India — Bench of Justices J.B. Pardiwala and R. Mahadevan.
States and UTs — enforce the rules through clinical establishment registration.

How It Works

Approved indications only: Hospitals may offer stem cell therapy as routine care only where it is approved. This blocks unproven "cures" sold to patients.
Autism in trials only: Any stem cell use for autism must be within an approved clinical trial. Trials have ethics oversight and informed consent safeguards.
Doctor accountability: Unauthorised administration, prescription, promotion or advertising beyond approved indications is professional misconduct under Regulation 7.22 of the IMC Regulations, 2002.
Hospital accountability: States can cancel registration and impose penalties under Sections 32 and 40 of the Clinical Establishments Act, 2010.
Drug-law cover: The Supreme Court held stem cells are a "drug" under the Drugs and Cosmetics Act, 1940, bringing them under the New Drugs and Clinical Trials Rules, 2019.

Why It Matters

Constitutional: The Court held that patient consent under Article 21 does not create a right to demand a particular treatment.
Ethical: Unproven therapy fails the standard of care owed to patients.
Social: Protects families of autistic children from costly, unproven treatments.
Federal: Health enforcement depends on States adopting and applying the Clinical Establishments Act.

Historical Background

2013: National Guidelines for Stem Cell Research treated all stem cell therapy other than approved uses as investigational, to be done only as clinical trials; oversight came from IC-SCR (institutional) and NAC-SCRT (national) committees.
2017: Revised National Guidelines for Stem Cell Research issued by ICMR and DBT, declaring use outside trials unethical.
9 February 2021: The Health Ministry clarified the definition of "stem cell derived products".

Previous Related Events

6 December 2022: NMC's Ethics and Medical Registration Board recommended treating such use as professional misconduct.
30 January 2026: Supreme Court judgment in Yash Charitable Trust v. Union of India.
5 September 2026: NMC advisory on stem cell therapy.

Static GK Connection

Article 21: Right to life includes the right to health and informed consent.
Health in the State List: Public health and hospitals are State subjects, so the Centre issues advisories and States enforce them.

India & World Comparison

Under India's 2013 guidelines, haematopoietic stem cell transplantation for blood disorders was the only approved stem cell therapy.
Like many regulators worldwide, India now treats unproven stem cell uses as experimental, allowed only in regulated trials.

Future Impact

The Supreme Court directed a pan-India authority to regulate stem cell research.
It also directed dedicated legislation on stem cell research.
Patients already on therapy were to be re-routed to clinical trials within four weeks of the judgment.

🔑 Key Points for Revision

Health Ministry advisory issued on 16 September 2026.
Routine stem cell therapy only for approved indications.
Autism: stem cell use only in duly approved clinical trials.
Addressed to States/UTs that adopted the Clinical Establishments Act, 2010.
Framework: National Guidelines for Stem Cell Research, 2017 (ICMR + DBT).
NMC advisory issued on 5 September 2026.
SC case: Yash Charitable Trust v. Union of India, 30 January 2026.
Bench: Justices J.B. Pardiwala and R. Mahadevan.
Stem cells are a "drug" under the Drugs and Cosmetics Act, 1940.
Misconduct under Regulation 7.22, IMC Regulations, 2002.
Penalties under Sections 32 and 40, Clinical Establishments Act, 2010.
2013 guidelines: only HSCT for blood disorders was approved therapy.
Oversight committees: IC-SCR (institutional) and NAC-SCRT (national).
SC directed a pan-India authority and dedicated legislation.
Patients to be moved to clinical trials within four weeks of judgment.

🧠 Concept Link (Static GK Deep Dive)

Core Concept: Regulation of Stem Cell Therapy in India

Definition: Stem cells are unspecialised cells that can develop into different cell types; therapy uses them to repair or replace tissue.
Constitutional / Legal Basis: Article 21 (right to life and health); Drugs and Cosmetics Act, 1940; New Drugs and Clinical Trials Rules, 2019; Clinical Establishments Act, 2010.
Scientific Principle: A therapy is "approved" only after trials prove safety and efficacy.
Link to this event: Autism therapy lacks proven efficacy, so it stays within trials.
Origin & History: 2013 guidelines treated all non-approved stem cell therapy as investigational.
Key milestone 1: 2017 — revised National Guidelines for Stem Cell Research by ICMR and DBT.
Key milestone 2: 30 January 2026 — Supreme Court judgment in Yash Charitable Trust.
Related Acts / Schemes / Treaties: IMC Regulations, 2002; Clinical Establishments Act, 2010; NDCT Rules, 2019.
Nodal Ministry / Body: Ministry of Health and Family Welfare; NMC for doctors; ICMR and DBT for guidelines.
India-specific relevance: Commercial clinics had marketed stem cell "cures" for autism.
Global comparison: Treating unproven uses as experimental is the standard approach of drug regulators.
Data point: Omitted — no verified statistic on stem cell clinics was available this run.
Common exam angle: Which body issued what, and which law applies to doctors vs hospitals.
Easy memory hook: "30-1, 5-9, 16-9" — SC ruling, NMC advisory, Health Ministry advisory.

❓ Practice MCQs

Q1. The Health Ministry's September 2026 advisory restricts stem cell therapy for which condition to approved clinical trials? [Easy]

A) Leukaemia

B) Thalassaemia

C) Autism Spectrum Disorder

D) Diabetes

Answer: C

Explanation: Therapeutic use of any stem cell in autism is restricted to duly approved clinical trials.

Q2. The Supreme Court judgment on stem cell therapy for autism was delivered in which case? [Easy]

A) Yash Charitable Trust v. Union of India

B) Common Cause v. Union of India

C) Puttaswamy v. Union of India

D) Paschim Banga Khet Mazdoor Samity v. State of West Bengal

Answer: A

Explanation: The Court decided Yash Charitable Trust v. Union of India on 30 January 2026.

Q3. The National Guidelines for Stem Cell Research referred to in the advisory were issued in which year? [Moderate]

A) 2010

B) 2013

C) 2019

D) 2017

Answer: D

Explanation: The advisory refers to the National Guidelines for Stem Cell Research, 2017, issued by ICMR and DBT.

Q4. Under which law can a State cancel the registration of a clinical establishment that violates the advisory? [Moderate]

A) Drugs and Cosmetics Act, 1940

B) Clinical Establishments (Registration and Regulation) Act, 2010

C) National Medical Commission Act, 2019

D) Epidemic Diseases Act, 1897

Answer: B

Explanation: Sections 32 and 40 of the Clinical Establishments Act, 2010, provide for penalties, including cancellation of registration.

Q5. Under which law did the Supreme Court hold that stem cells fall within the definition of "drug"? [Moderate]

A) Clinical Establishments Act, 2010

B) Indian Medical Council Regulations, 2002

C) Drugs and Cosmetics Act, 1940

D) Biological Diversity Act, 2002

Answer: C

Explanation: The Court treated stem cells as "drug" under Section 3(b)(i) of the Drugs and Cosmetics Act, 1940.

Q6. Which statement about the sequence of events is correct? [Tricky]

A) The Health Ministry advisory came before the Supreme Court judgment.

B) The NMC advisory was issued after the Health Ministry advisory.

C) The Supreme Court judgment was delivered in September 2026.

D) The NMC advisory of 5 September 2026 preceded the Health Ministry advisory of 16 September 2026.

Answer: D

Explanation: The SC ruled on 30 January 2026, the NMC advised on 5 September, and the Health Ministry on 16 September 2026.

Q7. Which of the following was a direction of the Supreme Court in the Yash Charitable Trust case? [Tricky]

A) A complete ban on all stem cell research in India

B) Setting up a pan-India authority to regulate stem cell research

C) Transfer of health to the Union List

D) Approval of stem cell therapy for autism as routine care

Answer: B

Explanation: The Court directed a pan-India authority and dedicated legislation; research through approved trials remains allowed.

Q8. Under India's 2013 stem cell guidelines, which was the only approved stem cell therapy? [Tricky]

A) Haematopoietic stem cell transplantation for blood disorders

B) Stem cell therapy for autism

C) Stem cell therapy for cerebral palsy

D) Embryonic stem cell therapy for spinal injury

Answer: A

Explanation: HSCT for haematological disorders was the only approved therapy; all others were investigational.

📜 Previous Year Question Style (PYQ)

PYQ 1:

The Supreme Court Bench in Yash Charitable Trust v. Union of India (2026) comprised:

A) D.Y. Chandrachud and J.B. Pardiwala

B) Sanjiv Khanna and R. Mahadevan

C) B.R. Gavai and K.V. Viswanathan

D) J.B. Pardiwala and R. Mahadevan

Answer: D

Explanation: The judgment of 30 January 2026 was delivered by Justices J.B. Pardiwala and R. Mahadevan.

PYQ 2:

Consider the following statements about the Health Ministry advisory of 16 September 2026:

It permits stem cell therapy as routine clinical care only for approved indications.
It bans all clinical trials of stem cells for autism.
Non-compliance may lead to cancellation of a clinical establishment's registration.

Which of the above statements is/are correct?

A) 1 only

B) 1 and 3 only

C) 2 and 3 only

D) 1, 2 and 3

Answer: B

Explanation: Statements 1 and 3 are correct; autism use is allowed in approved trials, so statement 2 is wrong.

PYQ 3:

Assertion (A): Offering stem cell therapy for autism outside approved clinical trials amounts to professional misconduct.

Reason (R): Stem cell therapy for autism lacks proven safety and efficacy, so offering it fails the standard of care owed to patients.

A) Both A and R are true, and R is the correct explanation of A

B) Both A and R are true, but R is not the correct explanation of A

C) A is true, but R is false

D) A is false, but R is true

Answer: A

Explanation: The Supreme Court held that unproven therapy fails the standard of care, which is why it is treated as misconduct.

✍️ Mains Answer Pointers

Question 1 (150 words): Why has the Government restricted stem cell therapy for autism to approved clinical trials?

The Government has restricted stem cell therapy for autism to approved clinical trials because its safety and efficacy are not proven.

In Yash Charitable Trust v. Union of India, decided on 30 January 2026, the Supreme Court held that such therapy cannot continue as a commercial activity. Offering an unproven treatment fails the standard of care, and consent given on inadequate information is not valid.

Acting on this, the NMC issued an advisory on 5 September 2026, and the Health Ministry advised States and UTs on 16 September 2026. Stem cell therapy is now routine care only for approved indications.

Enforcement uses two tracks: doctors face misconduct action under Regulation 7.22 of the IMC Regulations, 2002, and hospitals face penalties under the Clinical Establishments Act, 2010. States must now enforce these rules strictly.

Question 2 (250 words): Discuss the challenges in regulating emerging medical therapies in India, with reference to stem cell therapy.

Emerging therapies promise cures but often reach patients before evidence does. Stem cell therapy in India shows this gap between science, commerce and regulation.

India's approach has evolved in steps. The 2013 guidelines treated all non-approved stem cell therapy as investigational. The 2017 guidelines by ICMR and DBT declared use outside trials unethical. Yet clinics continued to market treatments, especially for autism.

The Supreme Court intervened on 30 January 2026 in Yash Charitable Trust v. Union of India. It held that stem cells are a "drug" under the Drugs and Cosmetics Act, 1940, that unproven therapy fails the standard of care, and that consent under Article 21 does not give a right to demand a particular treatment. It directed a pan-India authority and dedicated legislation.

Challenges remain. First, fragmented regulation: guidelines, drug rules, NMC regulations and the Clinical Establishments Act all apply. Second, federal limits: health is a State subject, and enforcement depends on States that have adopted the 2010 Act. Third, information asymmetry: desperate families may not judge scientific claims. Fourth, the need to protect genuine research while stopping commercial misuse.

The 16 September 2026 advisory is a step forward. Lasting reform needs the dedicated law the Court sought, a single regulator, public registries of approved trials, and patient awareness campaigns, so that innovation grows within ethical limits.

⚠️ Examiner Trap

Trap 1: Students confuse the NMC advisory with the Health Ministry advisory. The correct fact is NMC on 5 September 2026 and the Health Ministry on 16 September 2026.
Trap 2: A common wrong assumption is that all stem cell work on autism is banned. The reality is that it is allowed within duly approved clinical trials.
Trap 3: Many students miss that two different laws apply. Always remember doctors face action under the IMC Regulations, 2002, and hospitals under the Clinical Establishments Act, 2010.

🧭 Exam Tip

Prelims: case name, date, Bench, and the 2017 guidelines by ICMR and DBT are likely asks.
Mains: GS-2 (health governance, judiciary) — use it for questions on regulating medical innovation and patient rights.
Interview: expect a question on balancing medical innovation with patient safety.
Prediction: a statement-based question on stem cell regulation and the Clinical Establishments Act is likely.

Health Ministry Tightens Stem Cell Therapy Rules: Autism Treatment Only in Approved Clinical Trials

What Happened

When & Where

Advisory: 16 September 2026, New Delhi; addressed to States and UTs that adopted the Clinical Establishments Act, 2010.
NMC advisory: 5 September 2026.
Supreme Court judgment: 30 January 2026.

Who Is Involved

Ministry of Health and Family Welfare — issued the advisory.
National Medical Commission (NMC) — regulates medical professionals; issued its own advisory.
ICMR and Department of Biotechnology (DBT) — jointly issued the National Guidelines for Stem Cell Research, 2017.
Supreme Court of India — Bench of Justices J.B. Pardiwala and R. Mahadevan.
States and UTs — enforce the rules through clinical establishment registration.

How It Works

Approved indications only: Hospitals may offer stem cell therapy as routine care only where it is approved. This blocks unproven "cures" sold to patients.
Autism in trials only: Any stem cell use for autism must be within an approved clinical trial. Trials have ethics oversight and informed consent safeguards.
Doctor accountability: Unauthorised administration, prescription, promotion or advertising beyond approved indications is professional misconduct under Regulation 7.22 of the IMC Regulations, 2002.
Hospital accountability: States can cancel registration and impose penalties under Sections 32 and 40 of the Clinical Establishments Act, 2010.
Drug-law cover: The Supreme Court held stem cells are a "drug" under the Drugs and Cosmetics Act, 1940, bringing them under the New Drugs and Clinical Trials Rules, 2019.

Why It Matters

Constitutional: The Court held that patient consent under Article 21 does not create a right to demand a particular treatment.
Ethical: Unproven therapy fails the standard of care owed to patients.
Social: Protects families of autistic children from costly, unproven treatments.
Federal: Health enforcement depends on States adopting and applying the Clinical Establishments Act.

Historical Background

2013: National Guidelines for Stem Cell Research treated all stem cell therapy other than approved uses as investigational, to be done only as clinical trials; oversight came from IC-SCR (institutional) and NAC-SCRT (national) committees.
2017: Revised National Guidelines for Stem Cell Research issued by ICMR and DBT, declaring use outside trials unethical.
9 February 2021: The Health Ministry clarified the definition of "stem cell derived products".

Previous Related Events

6 December 2022: NMC's Ethics and Medical Registration Board recommended treating such use as professional misconduct.
30 January 2026: Supreme Court judgment in Yash Charitable Trust v. Union of India.
5 September 2026: NMC advisory on stem cell therapy.

Static GK Connection

Article 21: Right to life includes the right to health and informed consent.
Health in the State List: Public health and hospitals are State subjects, so the Centre issues advisories and States enforce them.

India & World Comparison

Under India's 2013 guidelines, haematopoietic stem cell transplantation for blood disorders was the only approved stem cell therapy.
Like many regulators worldwide, India now treats unproven stem cell uses as experimental, allowed only in regulated trials.

Future Impact

The Supreme Court directed a pan-India authority to regulate stem cell research.
It also directed dedicated legislation on stem cell research.
Patients already on therapy were to be re-routed to clinical trials within four weeks of the judgment.

🔑 Key Points for Revision

Health Ministry advisory issued on 16 September 2026.
Routine stem cell therapy only for approved indications.
Autism: stem cell use only in duly approved clinical trials.
Addressed to States/UTs that adopted the Clinical Establishments Act, 2010.
Framework: National Guidelines for Stem Cell Research, 2017 (ICMR + DBT).
NMC advisory issued on 5 September 2026.
SC case: Yash Charitable Trust v. Union of India, 30 January 2026.
Bench: Justices J.B. Pardiwala and R. Mahadevan.
Stem cells are a "drug" under the Drugs and Cosmetics Act, 1940.
Misconduct under Regulation 7.22, IMC Regulations, 2002.
Penalties under Sections 32 and 40, Clinical Establishments Act, 2010.
2013 guidelines: only HSCT for blood disorders was approved therapy.
Oversight committees: IC-SCR (institutional) and NAC-SCRT (national).
SC directed a pan-India authority and dedicated legislation.
Patients to be moved to clinical trials within four weeks of judgment.

🧠 Concept Link (Static GK Deep Dive)

Core Concept: Regulation of Stem Cell Therapy in India

Definition: Stem cells are unspecialised cells that can develop into different cell types; therapy uses them to repair or replace tissue.
Constitutional / Legal Basis: Article 21 (right to life and health); Drugs and Cosmetics Act, 1940; New Drugs and Clinical Trials Rules, 2019; Clinical Establishments Act, 2010.
Scientific Principle: A therapy is "approved" only after trials prove safety and efficacy.
Link to this event: Autism therapy lacks proven efficacy, so it stays within trials.
Origin & History: 2013 guidelines treated all non-approved stem cell therapy as investigational.
Key milestone 1: 2017 — revised National Guidelines for Stem Cell Research by ICMR and DBT.
Key milestone 2: 30 January 2026 — Supreme Court judgment in Yash Charitable Trust.
Related Acts / Schemes / Treaties: IMC Regulations, 2002; Clinical Establishments Act, 2010; NDCT Rules, 2019.
Nodal Ministry / Body: Ministry of Health and Family Welfare; NMC for doctors; ICMR and DBT for guidelines.
India-specific relevance: Commercial clinics had marketed stem cell "cures" for autism.
Global comparison: Treating unproven uses as experimental is the standard approach of drug regulators.
Data point: Omitted — no verified statistic on stem cell clinics was available this run.
Common exam angle: Which body issued what, and which law applies to doctors vs hospitals.
Easy memory hook: "30-1, 5-9, 16-9" — SC ruling, NMC advisory, Health Ministry advisory.

❓ Practice MCQs

Q1. The Health Ministry's September 2026 advisory restricts stem cell therapy for which condition to approved clinical trials? [Easy]

A) Leukaemia

B) Thalassaemia

C) Autism Spectrum Disorder

D) Diabetes

Answer: C

Explanation: Therapeutic use of any stem cell in autism is restricted to duly approved clinical trials.

Q2. The Supreme Court judgment on stem cell therapy for autism was delivered in which case? [Easy]

A) Yash Charitable Trust v. Union of India

B) Common Cause v. Union of India

C) Puttaswamy v. Union of India

D) Paschim Banga Khet Mazdoor Samity v. State of West Bengal

Answer: A

Explanation: The Court decided Yash Charitable Trust v. Union of India on 30 January 2026.

Q3. The National Guidelines for Stem Cell Research referred to in the advisory were issued in which year? [Moderate]

A) 2010

B) 2013

C) 2019

D) 2017

Answer: D

Explanation: The advisory refers to the National Guidelines for Stem Cell Research, 2017, issued by ICMR and DBT.

Q4. Under which law can a State cancel the registration of a clinical establishment that violates the advisory? [Moderate]

A) Drugs and Cosmetics Act, 1940

B) Clinical Establishments (Registration and Regulation) Act, 2010

C) National Medical Commission Act, 2019

D) Epidemic Diseases Act, 1897

Answer: B

Explanation: Sections 32 and 40 of the Clinical Establishments Act, 2010, provide for penalties, including cancellation of registration.

Q5. Under which law did the Supreme Court hold that stem cells fall within the definition of "drug"? [Moderate]

A) Clinical Establishments Act, 2010

B) Indian Medical Council Regulations, 2002

C) Drugs and Cosmetics Act, 1940

D) Biological Diversity Act, 2002

Answer: C

Explanation: The Court treated stem cells as "drug" under Section 3(b)(i) of the Drugs and Cosmetics Act, 1940.

Q6. Which statement about the sequence of events is correct? [Tricky]

A) The Health Ministry advisory came before the Supreme Court judgment.

B) The NMC advisory was issued after the Health Ministry advisory.

C) The Supreme Court judgment was delivered in September 2026.

D) The NMC advisory of 5 September 2026 preceded the Health Ministry advisory of 16 September 2026.

Answer: D

Explanation: The SC ruled on 30 January 2026, the NMC advised on 5 September, and the Health Ministry on 16 September 2026.

Q7. Which of the following was a direction of the Supreme Court in the Yash Charitable Trust case? [Tricky]

A) A complete ban on all stem cell research in India

B) Setting up a pan-India authority to regulate stem cell research

C) Transfer of health to the Union List

D) Approval of stem cell therapy for autism as routine care

Answer: B

Explanation: The Court directed a pan-India authority and dedicated legislation; research through approved trials remains allowed.

Q8. Under India's 2013 stem cell guidelines, which was the only approved stem cell therapy? [Tricky]

A) Haematopoietic stem cell transplantation for blood disorders

B) Stem cell therapy for autism

C) Stem cell therapy for cerebral palsy

D) Embryonic stem cell therapy for spinal injury

Answer: A

Explanation: HSCT for haematological disorders was the only approved therapy; all others were investigational.

📜 Previous Year Question Style (PYQ)

PYQ 1:

The Supreme Court Bench in Yash Charitable Trust v. Union of India (2026) comprised:

A) D.Y. Chandrachud and J.B. Pardiwala

B) Sanjiv Khanna and R. Mahadevan

C) B.R. Gavai and K.V. Viswanathan

D) J.B. Pardiwala and R. Mahadevan

Answer: D

Explanation: The judgment of 30 January 2026 was delivered by Justices J.B. Pardiwala and R. Mahadevan.

PYQ 2:

Consider the following statements about the Health Ministry advisory of 16 September 2026:

It permits stem cell therapy as routine clinical care only for approved indications.
It bans all clinical trials of stem cells for autism.
Non-compliance may lead to cancellation of a clinical establishment's registration.

Which of the above statements is/are correct?

A) 1 only

B) 1 and 3 only

C) 2 and 3 only

D) 1, 2 and 3

Answer: B

Explanation: Statements 1 and 3 are correct; autism use is allowed in approved trials, so statement 2 is wrong.

PYQ 3:

Assertion (A): Offering stem cell therapy for autism outside approved clinical trials amounts to professional misconduct.

Reason (R): Stem cell therapy for autism lacks proven safety and efficacy, so offering it fails the standard of care owed to patients.

A) Both A and R are true, and R is the correct explanation of A

B) Both A and R are true, but R is not the correct explanation of A

C) A is true, but R is false

D) A is false, but R is true

Answer: A

Explanation: The Supreme Court held that unproven therapy fails the standard of care, which is why it is treated as misconduct.

✍️ Mains Answer Pointers

Question 1 (150 words): Why has the Government restricted stem cell therapy for autism to approved clinical trials?

The Government has restricted stem cell therapy for autism to approved clinical trials because its safety and efficacy are not proven.

Question 2 (250 words): Discuss the challenges in regulating emerging medical therapies in India, with reference to stem cell therapy.

Emerging therapies promise cures but often reach patients before evidence does. Stem cell therapy in India shows this gap between science, commerce and regulation.

⚠️ Examiner Trap

Trap 1: Students confuse the NMC advisory with the Health Ministry advisory. The correct fact is NMC on 5 September 2026 and the Health Ministry on 16 September 2026.
Trap 2: A common wrong assumption is that all stem cell work on autism is banned. The reality is that it is allowed within duly approved clinical trials.
Trap 3: Many students miss that two different laws apply. Always remember doctors face action under the IMC Regulations, 2002, and hospitals under the Clinical Establishments Act, 2010.

🧭 Exam Tip

Prelims: case name, date, Bench, and the 2017 guidelines by ICMR and DBT are likely asks.
Mains: GS-2 (health governance, judiciary) — use it for questions on regulating medical innovation and patient rights.
Interview: expect a question on balancing medical innovation with patient safety.
Prediction: a statement-based question on stem cell regulation and the Clinical Establishments Act is likely.